Gastroesophageal Junction Carcinoma clinical trials
8 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
- A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
- Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Gastroesophageal Junction Carcinoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.